|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
23
|
|
pubmed:dateCreated |
2009-8-7
|
|
pubmed:abstractText |
It has been postulated that castration-resistant prostate cancer (CRPC) commonly remains hormone dependent. Abiraterone acetate is a potent, selective, and orally available inhibitor of CYP17, the key enzyme in androgen and estrogen biosynthesis.
|
|
pubmed:grant |
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Aug
|
|
pubmed:issn |
1527-7755
|
|
pubmed:author |
pubmed-author:A'HernRogerR,
pubmed-author:AttardGerhardtG,
pubmed-author:DearnaleyDavidD,
pubmed-author:DowsettMitchM,
pubmed-author:FolkerdElizabethE,
pubmed-author:KayeStan BSB,
pubmed-author:KheohThianT,
pubmed-author:LeeGloriaG,
pubmed-author:MaierGalG,
pubmed-author:MessiouChristinaC,
pubmed-author:MolifeL RhodaLR,
pubmed-author:MolinaArturoA,
pubmed-author:OlmosDavidD,
pubmed-author:OommenNikhil BabuNB,
pubmed-author:ParkerChristopherC,
pubmed-author:ReidAlison H MAH,
pubmed-author:SinhaRajeshR,
pubmed-author:ThompsonEmildaE,
pubmed-author:de BonoJohann SJS
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
10
|
|
pubmed:volume |
27
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
3742-8
|
|
pubmed:dateRevised |
2010-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:19470933-Adrenal Cortex Hormones,
pubmed-meshheading:19470933-Aged,
pubmed-meshheading:19470933-Aged, 80 and over,
pubmed-meshheading:19470933-Androgen Antagonists,
pubmed-meshheading:19470933-Androstenols,
pubmed-meshheading:19470933-Antineoplastic Agents, Hormonal,
pubmed-meshheading:19470933-Disease Progression,
pubmed-meshheading:19470933-Drug Administration Schedule,
pubmed-meshheading:19470933-Drug Resistance, Neoplasm,
pubmed-meshheading:19470933-Enzyme Inhibitors,
pubmed-meshheading:19470933-Humans,
pubmed-meshheading:19470933-Kaplan-Meier Estimate,
pubmed-meshheading:19470933-Male,
pubmed-meshheading:19470933-Middle Aged,
pubmed-meshheading:19470933-Neoplasms, Hormone-Dependent,
pubmed-meshheading:19470933-Prospective Studies,
pubmed-meshheading:19470933-Prostate-Specific Antigen,
pubmed-meshheading:19470933-Prostatic Neoplasms,
pubmed-meshheading:19470933-Steroid 17-alpha-Hydroxylase,
pubmed-meshheading:19470933-Testosterone
|
|
pubmed:year |
2009
|
|
pubmed:articleTitle |
Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer.
|
|
pubmed:affiliation |
Royal Marsden National Health Service Foundation Trust, Sutton, Surrey, United Kingdom.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't,
Clinical Trial, Phase II,
Clinical Trial, Phase I
|
